Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms
A little less than a week before AstraZeneca’s takeover of Alexion is expected to be completed, the rare disease biotech offered up a cut of data for its Soliris successor.
In a Phase III study for Ultomiris looking at adults with generalized myasthenia gravis, the drug met its primary endpoint of significantly improving scores on a patient-reported assessment compared to placebo after 26 weeks, Alexion announced Thursday afternoon. Alexion hopes the topline results represent what could be Ultomiris’ third approval, after it notched OKs for a rare blood disorder called PNH and an ultra-rare chronic disease that damages the kidneys.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
